Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$26.64 - $40.31 $14,199 - $21,485
533 Added 2.92%
18,797 $661,000
Q4 2023

Feb 13, 2024

BUY
$19.95 - $31.0 $21,027 - $32,674
1,054 Added 6.12%
18,264 $527,000
Q3 2023

Nov 13, 2023

BUY
$21.33 - $59.42 $54,626 - $152,174
2,561 Added 17.48%
17,210 $394,000
Q2 2023

Aug 04, 2023

BUY
$34.33 - $62.11 $76,487 - $138,381
2,228 Added 17.94%
14,649 $839,000
Q1 2023

May 12, 2023

BUY
$26.01 - $48.69 $6,450 - $12,075
248 Added 2.04%
12,421 $467,000
Q4 2022

Feb 10, 2023

SELL
$24.14 - $30.37 $1,086 - $1,366
-45 Reduced 0.37%
12,173 $325,000
Q3 2022

Nov 14, 2022

BUY
$22.23 - $33.37 $3,845 - $5,773
173 Added 1.44%
12,218 $346,000
Q2 2022

Aug 12, 2022

BUY
$19.74 - $43.01 $30,360 - $66,149
1,538 Added 14.64%
12,045 $261,000
Q1 2022

May 13, 2022

SELL
$36.25 - $52.02 $26,788 - $38,442
-739 Reduced 6.57%
10,507 $422,000
Q4 2021

Feb 11, 2022

SELL
$43.27 - $65.72 $4,413 - $6,703
-102 Reduced 0.9%
11,246 $533,000
Q3 2021

Nov 12, 2021

SELL
$53.61 - $67.5 $14,474 - $18,225
-270 Reduced 2.32%
11,348 $643,000
Q2 2021

Aug 13, 2021

BUY
$45.13 - $64.99 $157,909 - $227,400
3,499 Added 43.1%
11,618 $667,000
Q1 2021

May 07, 2021

BUY
$29.77 - $84.85 $654 - $1,866
22 Added 0.27%
8,119 $514,000
Q4 2020

Feb 12, 2021

SELL
$25.66 - $34.55 $2,360 - $3,178
-92 Reduced 1.12%
8,097 $272,000
Q3 2020

Nov 04, 2020

SELL
$22.51 - $30.11 $4,186 - $5,600
-186 Reduced 2.22%
8,189 $224,000
Q2 2020

Aug 12, 2020

BUY
$12.65 - $29.57 $25,717 - $60,115
2,033 Added 32.06%
8,375 $227,000
Q1 2020

May 04, 2020

BUY
$10.84 - $20.85 $35,186 - $67,679
3,246 Added 104.84%
6,342 $93,000
Q4 2019

Feb 05, 2020

SELL
$13.02 - $19.5 $325 - $487
-25 Reduced 0.8%
3,096 $53,000
Q3 2019

Nov 08, 2019

BUY
$17.46 - $29.05 $54,492 - $90,665
3,121 New
3,121 $57,000

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $2.19B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.